65 U.S. Mayors to Join OraSure Technologies and the National Association of People with AIDS in Fourth Annual 'Mayors Campaign a
23 6월 2008 - 7:00PM
Business Wire
OraSure Technologies, Inc. (NASDAQ: OSUR) and the National
Association of People with AIDS (NAPWA) announced today that more
than 65 mayors and/or Department of Health offices in major
metropolitan cities nationwide have committed their participation
and support for the fourth annual Mayors Campaign Against HIV�, a
national campaign to encourage testing for HIV and promote the
benefits of knowing one�s HIV status. The Campaign is sponsored by
NAPWA and OraSure, the manufacturer of the OraQuick ADVANCE� Rapid
HIV-1/2 Antibody Test, in observance of National HIV Testing Day on
Friday, June 27, 2008. Now in its 14th year, National HIV Testing
Day is an annual event led by NAPWA to encourage the millions of
Americans who are at-risk for HIV to receive voluntary HIV
counseling and testing. According to the Centers for Disease
Control and Prevention, approximately 1.1 million individuals in
the United States are infected with the HIV virus, yet more than
one-quarter do not know they have the disease. For this year�s
Campaign, OraSure and NAPWA have collaborated with a record number
of mayors, city public health departments and community-based
organizations across the country to urge HIV testing and prevention
among their constituencies. The cities participating in the
Campaign include Baltimore, Chicago, Houston, New York City,
Phoenix, San Francisco and Tuskegee, AL. Several mayors have also
committed to getting tested on June 27, while others are issuing
proclamations or holding press conferences to encourage individuals
to get screened for HIV. �We are very pleased to be joining forces
with NAPWA and the participating mayors again this year as we
publicly unite in the fight against HIV/AIDS through our Mayors
Campaign Against HIV�,� said Douglas A. Michels, President and
Chief Executive Officer of OraSure Technologies. �As the nation's
only FDA-approved rapid HIV test for use with oral fluid and blood,
the OraQuick ADVANCE� Rapid HIV-1/2 Antibody Test will help to get
more people tested and enable HIV-positive people to learn their
status earlier so they can access care sooner. We are committed to
working in partnership with national, state and local health
agencies to make the OraQuick ADVANCE� test available to all who
need it.� �Each year, National HIV Testing Day brings together
thousands of local health departments, community organizations and
HIV/AIDS advocacy groups nationwide to encourage early diagnosis
and routine testing for HIV/AIDS, and the Mayors Campaign Against
HIV� helps to further support this mission,� said Frank Oldham,
Jr., NAPWA�s President and CEO. �Education remains one of the most
powerful tools in the fight against HIV/AIDS. By working in
partnership with OraSure and mayors around the country, we hope to
educate hundreds of thousands nationwide on the need for HIV
testing and prevention. We are thankful for the dedication and
support of both OraSure and each mayoral office participating in
the campaign.� In appreciation of the mayors� involvement in the
Campaign, NAPWA and OraSure will donate more than 20,000 OraQuick
ADVANCE� Rapid HIV-1/2 Antibody Tests to city health departments
and community-based organizations throughout the country. OraQuick
ADVANCE� is a rapid screening test for antibodies to both HIV-1 and
HIV-2, and is the only FDA-approved test that can be used at the
point of care with oral fluid, finger stick and venipuncture whole
blood and plasma samples. OraQuick ADVANCE� is currently in use at
many health-care organizations across the country, including the
New York City Department of Health and Mental Hygiene. In data
recently presented at the HIV Prevention Leadership Summit in
Detroit, Mi., June 11-14, several organizations reported on
preference for and high accuracy of rapid HIV testing with oral
fluid using the OraQuick ADVANCE test.�Recent national data
indicates that OraQuick ADVANCE� has a very high degree of accuracy
with oral fluid � at rates that are within the U.S. Food and Drug
Administration�s approved and expected range of performance
(specificity 99.6-99.9%) for the product. Based on aggregate data
compiled by OraSure from participating surveillance sites
nationwide for 2007 through May 2008, results for over 250,000 oral
fluid tests were reported with a specificity rate of 99.8%. The
data was generated at more than 400 sites, including public health
clinics, community-based organizations, hospitals and outreach
settings. �The use of rapid oral fluid HIV testing has provided
greater opportunity to identify HIV infected individuals and ensure
that those diagnosed with HIV are linked into care immediately,�
Mr. Michels said. �Because of its convenience and high degree of
accuracy, oral fluid testing with OraQuick ADVANCE� has played a
critical role in the fight against HIV/AIDS and will undoubtedly
continue to be the preferred method of HIV screening in many
settings.� About the National Association of People with AIDS
(NAPWA-US) The National Association of People with AIDS (NAPWA-US)
is the oldest national AIDS organization in the United States and
the oldest national network of people living with HIV/AIDS in the
world. Founded in 1983, NAPWA is a non-profit membership
organization that advocates on behalf of all people living with HIV
and AIDS in order to end the pandemic and the human suffering it
causes. NAPWA has several initiatives designed to promote access to
and the utilization of HIV prevention and treatment and reduce
stigma towards HIV-positive people. Nearly one million Americans
are living with HIV and more than 40 million people around the
world are infected. We will be here until there is a cure. More
information on NAPWA and national HIV Testing Day can be found at
http://www.napwa.org. About OraSure Technologies OraSure
Technologies develops, manufactures and markets oral fluid specimen
collection devices using proprietary oral fluid technologies,
diagnostic products including immunoassays and other in vitro
diagnostic tests, and other medical devices. These products are
sold in the United States as well as internationally to various
clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. OraSure Technologies is the leading supplier
of oral-fluid collection devices and assays to the life insurance
industry and public health markets for the detection of HIV. In
addition, the Company supplies oral-fluid testing solutions for
drugs of abuse testing. For more information on the Company, please
go to http://www.orasure.com.
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024